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We have identified a cooperative interaction between
radiation and intratumoral injection of anti-GD2 immu-
nocytokine (hu14.18-IL2) in murine tumor models. In a
moderate size (~200 mm3), single tumor, B78 melanoma
model this combination results in complete tumor
regression in 71% of animals and a memory T cell
response. We hypothesized that intratumoral immunocy-
tokine would improve local and abscopal response to com-
bined radiation and anti-CTLA-4 antibody.
Mice bearing large B78 tumors (~500mm3) were treated
with single fraction (12Gy) or sham radiation, intratumoral
immunocytokine or control IgG (50μg days 6-10 after
radiation), and intraperitoneal IgG2a anti-CTLA-4 or con-
trol IgG (100μg days 3, 6, and 9 after radiation). In this
large tumor model the effect of combined radiation and
immunocytokine was reduced (27% complete response)
and addition of immunocytokine to radiation and anti-
CTLA-4 improved tumor response (73% complete
response) and animal survival compared to doublet com-
binations of these agents. In a model of microscopic meta-
static disease generated by IV injection of animals bearing
large primary B78 tumors (~500mm3) with 4x105 GD2-
deficient B16 melanoma cells (parental to B78) on the day
of radiation, we observed improved survival with the addi-
tion of immunocytokine to combined radiation and anti-
CTLA-4.
However, in a model of established metastatic disease
with a moderate size (~200 mm3) primary B78 melanoma
and a palpable (~50 mm3) distant B78 tumor we did not
observe an abscopal response when treating the primary
tumor with radiation and intratumoral immunocytokine.
Strikingly, when compared to animals with a single
tumor we observed a profound inhibitory effect of the
non-radiated second tumor such that primary tumor
response to radiation and immunocytokine was indistinct
from radiation alone in this two-tumor model. Delivering
radiation to both the primary and secondary tumors
eliminated this inhibitory effect of the secondary tumor.
In this two-tumor model we combined primary tumor
radiation and intratumoral immunocytokine with intraper-
itoneal IgG2b or IgG2a anti-CTLA-4. Both isotypes inhibit
CTLA-4 activity but the latter has a reportedly greater
ability to deplete intratumoral regulatory T cells (Tregs).
While IgG2b anti-CTLA-4 had minimal effect on primary
tumor response to radiation and immunocytokine, IgG2a
anti-CTLA-4 rendered 80% of animals disease-free when
given with radiation and immunocytokine, implicating
Tregs in the suppressive effect of the second tumor on
primary tumor response. In this two-tumor model, combi-
nation of radiation, immunocytokine, and IgG2a anti-
CTLA-4 enhanced primary tumor and abscopal response
as well as survival compared to doublet combinations.
Clinical trial designs to explore these findings will be
presented.
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